Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

upplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Johnson 26 Johnson Honors 2009 Recipient of The Dr Paul Janssen Award for Biomedical Research 13876 1Johnson 26 Johnson Honors 2009 Recipient of The Dr Paul Janssen Award for Biomedical Research 13876 2Johnson 26 Johnson Honors 2009 Recipient of The Dr Paul Janssen Award for Biomedical Research 13876 3Johnson 26 Johnson Honors 2009 Recipient of The Dr Paul Janssen Award for Biomedical Research 13876 4Johnson 26 Johnson Honors 2009 Recipient of The Dr Paul Janssen Award for Biomedical Research 13876 5Analysis confirms that nano related research has strong multidisciplinary roots 13875 1Analysis confirms that nano related research has strong multidisciplinary roots 13875 2Analysis confirms that nano related research has strong multidisciplinary roots 13875 3Analysis confirms that nano related research has strong multidisciplinary roots 13875 4Rate of teen binge drinking cut more than 1 3 by prevention system 56343 1Rate of teen binge drinking cut more than 1 3 by prevention system 56343 2Rate of teen binge drinking cut more than 1 3 by prevention system 56343 3
...SAN DIEGO and SUNNYVALE, Calif., April 16 ,Pharmac...linical results,demonstrating the anti-tumor activ...tor VIIa inhibitor. The data were presented during...r Cancer Research (AACR) being,held this week in S...l models of human pancreatic tumors,treatment with...
...ROCHESTER, Minn., April 16, 2008 A new Mayo,Clini...elp protect against,mild cognitive impairment, a d...lved in thinking abilities. This study will be pre... Meeting in Chicago on April 16., Individuals wit...y well,in everyday activities, but often have diff...
Other Medicine Technology:Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer 2Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer 3Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 2
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
(Date:12/4/2009)Increasing exercise, water and fruit consumption leads to success, study finds , , FRIDAY, Dec. 4 (HealthDay News) -- Increased exercise, reduced soda consumption and self-weighing are among
(Date:12/4/2009)BOSTON, Dec. 4 Substantial progress has been made over the last 15 years in the healthcare community,s ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy man
Breaking Medicine News(10 mins):Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Teens Lose More Weight Using Healthy Strategies 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4
... YORK, Jan. 6 During 2009, millions of Americans ...es and injections or be given mind-altering drugs ...heir physicians recognize and treat the actual sou...ost common disabling pain experienced by Americans...
... ST. LOUIS, Jan. 6 "Psych Yourself Skinny" is a c...elf, with a 28-day schedule of,meditations, freest...essions,explicit visual motivators and blunt advic...inny self, even if you,re not creative.,This book ...
...ANN ARBOR, Mich. University of Michigan researche...ys a critical role in not one, but two processes a...eins involved in responding to DNA damage that can...s lead author. Ferguson is an assistant professor ...
... DIEGO, Jan. 6 SpectraScience, Inc. (OTC Bulletin...mpany, today announced that it has been awarded U....aratus for evaluating image focus. , , Jim Hitch... provides methods of focusing an instrument for th...
...LAS, Jan. 6 Paul Spiegelman, author of Why Is Ev...ivity and Profit , knows what it takes to create a... healthcare-exclusive call center Spiegelman co-fo...he healthcare industry. , , "Tough economic times...
...TLAKE VILLAGE, Calif., Jan. 6 Specialists On Call...the states in which it provides service, including...vider of emergency neurology on-call services to h.../LAW515LOGO ) , , Dr. Joe Peterson, CEO, describe...
Other Medicine News:Health News:Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D. 2Health News:Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D. 3Health News:Unnecessary Spinal Surgery Will Waste Billions of Dollars in 2009 and Patients Will Continue to Suffer Unless the Primary Cause of Most Back Pain is Treated, Says Pain Specialist Norman Marcus, M.D. 4Health News:'Psych Yourself Skinny' Lose Weight the Fun & Creative Way in 2009! 2Health News:Protein's essential role in repairing damaged cells revealed 2Health News:Protein's essential role in repairing damaged cells revealed 3Health News:SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus 2Health News:SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus 3Health News:Author Shares Nine Resolutions for 2009 to Create a Winning Corporate Culture 2Health News:Author Shares Nine Resolutions for 2009 to Create a Winning Corporate Culture 3Health News:Specialists On Call Expands Access to Emergency Neurology On-Call Services in North Carolina 2
ScanGel® Incubator
...erent sized High-Throughput Submarine Systems are ...icrotitre plates. Analyze high numbers of cloning ...or PCR products simultaneously. The microtitre for...d speed with additional savings in expensive reage...
...ROTEAN 3 Dodeca cell runs up to 12 mini gels under... gels can be poured 12 at a time with the new Mode...ting chamber, eliminating sources of variation and...el precast gels offer the convenience and reproduc...
...ion Dodeca cell, a component of the Criterion prec...on gels in a single run. Criterion gels are wider ...ni gel. They accommodate Bio-Rad's 11 cm ReadyStri...f separation and speed in 2-D electrophoretic appl...
Medicine Products: